<DOC>
	<DOCNO>NCT01811875</DOCNO>
	<brief_summary>Primary objective : To assess post-marketing immunogenicity Optivate® monitoring plasma inhibitor level least 100 Exposure Days ( EDs ) subject . Secondary objective : To assess efficacy tolerability monitoring FVIII recovery adverse event</brief_summary>
	<brief_title>Multicentre , Non-controlled , Prospective , Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment Subjects With Severe Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Written inform consent , less 18 year age write assent ( possible ) parent/guardian 's write informed consent . Severe haemophilia A ( &lt; 1 % # FVIII : C ) . Previously Treated Patients ( PTPs ) &gt; 150 exposure day prior Factor VIII therapy ( least last 50 EDs 2 year treatment confirm way subject record ) . Immunocompetent CD4 count &gt; 200 / µl . HIV negative viral load &lt; 200 particle / µl . subject suffer severe haemophilia A ( &lt; 2 % ) may enrol , approval BPL . Subjects Factor VIII &lt; 2 % may constitute 50 % total patient population . A separate statistical evaluation conduct &lt; 1 % &lt; 2 % population . • History inhibitor development FVIII positive result Nijmegen Bethesda screening ( quantitative result &gt; 0.6 BU ) prior administration Optivate® . Known suspect hypersensitivity investigational medicinal product excipients . Clinically significant liver disease , renal disease , coagulopathy haemophilia A . History unreliability non cooperation ( include able complete study diary ) . Participating , take part another trial within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Haemophilia A</keyword>
</DOC>